ReviewCancers2020

Comparative Efficacy and Safety of Anti-PD-1/PD-L1 Immune Checkpoint Inhibitors for Refractory or Relapsed Advanced Non-Small-Cell Lung Cancer-A Systematic Review and Network Meta-Analysis.

Koichi Ando et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.